Akèy › Kansè Glann Salivè › Tennessee › Nashville
Etid klinik pou Kansè Glann Salivè nan Nashville, TN
5 etid pou Kansè Glann Salivè ap chèche patisipan nan sit nan ak bò kote Nashville (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
DESTINY-PANTUMOUR04
Ap rekriteEtid obsèvasyon
- Research Site, Nashville
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Ap rekriteFaz 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Ap rekriteFaz 2
- SCRI Oncology Partners, Nashville
Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville
- Vanderbilt-Ingram Cancer Center at Franklin, Nashville
- Veterans Affairs Medical Center - Nashville, Nashville
- ak 1 plis
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Ap rekriteFaz 1/2
- Tennessee Oncology, Nashville
Etid Kansè Glann Salivè nan lòt vil
- Houston, TX5 etid
- Boston, MA5 etid
- New York City, NY4 etid
- Philadelphia, PA3 etid
- Dallas, TX3 etid
- Highlands Ranch, CO3 etid
Lòt etid nan Nashville
- Kansè Poumon ki pa ti selil97 etid
- Kansè nan tete81 etid
- Kansè Metastatik70 etid
- Kansè kolorektal69 etid
- Kansè (tout kalite)65 etid
- Kansè ovè49 etid
- Kansè pwostat43 etid
- Kansè poumon40 etid
- Karsinòm selil skuamèz tèt ak kou39 etid
- Kansè pankreyas39 etid
- Kansè Endomèt38 etid
- Melanom33 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.